YZJ-4729
/ Yangtze River Pharmaceutical Group
- LARVOL DELTA
Home
Next
Prev
1 to 11
Of
11
Go to page
1
June 30, 2026
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
(clinicaltrials.gov)
- P3 | N=560 | Active, not recruiting | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Active, not recruiting
Enrollment closed • Pain
June 30, 2026
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery
(clinicaltrials.gov)
- P2 | N=150 | Completed | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Not yet recruiting ➔ Completed
Trial completion • Musculoskeletal Pain • Orthopedics • Pain
June 29, 2026
A Phase ? Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery
(clinicaltrials.gov)
- P2 | N=179 | Completed | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Active, not recruiting ➔ Completed
Trial completion • Pain
January 31, 2026
A Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and QT Interval Effects of a Single Dose of YZJ-4729 Tartrate Injection
(ChiCTR)
- P=N/A | N=24 | Not yet recruiting | Sponsor: The Third Xiangya Hospital, Central South University; The Third Xiangya Hospital of Central South University
New trial • Pain
June 28, 2025
Development and validation of an LC-MS/MS method for quantifying a new G protein selective μ-opioid receptor agonist YZJ-4729 and its major metabolite M10 in human plasma to support a phase I study in healthy subjects.
(PubMed, J Chromatogr B Analyt Technol Biomed Life Sci)
- "The method showed excellent linearity across the ranges of 0.500 to 500 ng/mL for YZJ-4729 and 0.0500 to 50.0 ng/mL for M10. The method was utilized to assess the plasma concentrations of YZJ-4729 and M10 in healthy volunteers after a 30-min intravenous infusion in the phase I clinical study, and the clinical pharmacokinetic profiles of YZJ-4729 and M10 were described."
Journal • P1 data
June 06, 2025
Efficacy and safety of YZJ-4729 tartrate injection for postoperative analgesia after abdominal surgery: a multicenter, randomized, double-blind, placebo and positive drug parallel controlled phase III clinical trial
(ChiCTR)
- P3 | N=560 | Not yet recruiting | Sponsor: The Third Xiangya Hospital of Central South University; Third Xiangya Hospital of Central South University
New P3 trial • Pain
March 31, 2025
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Orthopedic Surgery
(clinicaltrials.gov)
- P2 | N=150 | Not yet recruiting | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
New P2 trial • Musculoskeletal Pain • Orthopedics • Pain
March 24, 2025
A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery
(clinicaltrials.gov)
- P3 | N=560 | Not yet recruiting | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
New P3 trial • Pain
November 08, 2024
A Phase 1 Study of YZJ-4729 Tartrate Injection in Healthy Chinese Subjects
(clinicaltrials.gov)
- P1 | N=66 | Completed | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
New P1 trial
November 08, 2024
A Phase Ⅱ Study to Evaluate the Efficacy and Safety of YZJ-4729 in Patients With Moderate to Severe Acute Pain After Abdominal Surgery
(clinicaltrials.gov)
- P2 | N=179 | Active, not recruiting | Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.
New P2 trial • Surgery • Pain
January 24, 2024
Pharmacokinetics, metabolite profiling, safety and tolerability of YZJ-4729 tartrate, a novel G protein-biased μ-opioid receptor agonist, in healthy Chinese subjects.
(PubMed, Front Pharmacol)
- " The clinical study results laid a foundation for the further clinical studies of YZJ-4729 in patients. Clinical Trial Registration: http://www.chinadrugtrials.org.cn, identifier CTR20222574."
Clinical • Journal • PK/PD data • Pain
1 to 11
Of
11
Go to page
1